Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: A potential role for infantile spasms and Lennox-Gastaut syndrome

Epilepsy and Behavior

Volumn 47, Issue , 2015, Pages 138-141

  Hussain, Shaun A ^a   Zhou, Raymond ^a   Jacobson, Catherine ^a   Weng, Julius ^a   Cheng, Emily ^a   Lay, Johnson ^a   Hung, Phoebe ^a   Lerner, Jason T ^a   Sankar, Raman ^a  

^a MATTEL CHILDREN S HOSPITAL   (United States)

Author keywords

Cannabidiol; Cannabis; Infantile spasms; Lennox Gastaut syndrome; Marijuana; Survey; West syndrome

Indexed keywords

ANTICONVULSIVE AGENT; CANNABIDIOL; CANNABIS; CLOBAZAM; PHENYTOIN; PLANT EXTRACT;

AGGRESSION; ALERTNESS; ANXIETY; ARTICLE; BENIGN CHILDHOOD EPILEPSY; CHILD; CONFUSION; DECREASED APPETITE; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HUMAN; INCREASED APPETITE; INFANT; INFANTILE SPASM; INSOMNIA; KETOGENIC DIET; LENNOX GASTAUT SYNDROME; MAJOR CLINICAL STUDY; MOOD; NAUSEA; OBSESSION; PARENT; RASH; SLEEP; UNSPECIFIED SIDE EFFECT; VAGUS NERVE STIMULATION; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION; ADOLESCENT; AFFECT; ATTENTION; CHEMISTRY; COMPLICATION; DRUG RESISTANT EPILEPSY; EPILEPSY; FEMALE; HEALTH CARE SURVEY; MALE; ONSET AGE; PSYCHOLOGY; SEIZURES; SPASMS, INFANTILE; SYNDROME; YOUNG ADULT;

ADOLESCENT; AFFECT; AGE OF ONSET; ANTICONVULSANTS; ATTENTION; CANNABIDIOL; CANNABIS; CHILD; DRUG RESISTANT EPILEPSY; EPILEPSY; FEMALE; HEALTH CARE SURVEYS; HUMANS; INFANT; LENNOX GASTAUT SYNDROME; MALE; PLANT EXTRACTS; SEIZURES; SLEEP; SPASMS, INFANTILE; SYNDROME; YOUNG ADULT;

EID: 84937639502     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2015.04.009     Document Type: Article

References (11)

1. Hussain S.A., Sankar R. Pharmacologic treatment of intractable epilepsy in children: a syndrome-based approach. Semin Pediatr Neurol 2011, 18:171-178.
2. Szaflarski J.P., Bebin E.M. Cannabis, cannabidiol, and epilepsy - from receptors to clinical response. Epilepsy Behav 2014, 41C:277-282.
3. Devinsky O., Cilio M.R., Cross H., Fernandez-Ruiz J., French J., Hill C., et al. Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia 2014, 55:791-802.
4. Sirven J.I. Cannabis, cannabidiol, and epilepsies: the truth is somewhere in the middle. Epilepsy Behav 2014, 41:270-271.
5. Maa E., Figi P. The case for medical marijuana in epilepsy. Epilepsia 2014, 55:783-786.
6. Cilio M.R., Thiele E.A., Devinsky O. The case for assessing cannabidiol in epilepsy. Epilepsia 2014, 55:787-790.
7. Porter B.E., Jacobson C. Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy. Epilepsy Behav 2013, 29:574-577.
8. Mathern G.W., Beninsig L., Nehlig A. Fewer specialists support using medical marijuana and CBD in treating epilepsy patients compared with other medical professionals and patients: result of Epilepsia's survey. Epilepsia 2015, 56:1-6.
9. Dulac O. Epileptic encephalopathy. Epilepsia 2001, 42:23-26.
10. Guerrini R. Dravet syndrome: the main issues. Eur J Paediatr Neurol 2012, 16(Supplement 1):S1-S4.
11. Stott C., White L., Wright S., Wilbraham D., Guy G. A phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of rifampicin, ketoconazole, and omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers. SpringerPlus 2013, 2:236.